go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

Bayer Limited

Bayer Limited
The Atrium, Blackthorn Road, Dublin 18,
Telephone: +353 1 2999 313
Fax: +353 1 2061 456
Summary of Product Characteristics last updated on medicines.ie: 01/11/2011
SPC Beta-Adalat

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 01/11/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   25-Oct-2011
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company

Update to Sections 6.1 and 10.


6.1 List of Excipients

Update to Printing ink section:

Deletion of Soya Lecithin and Antifoam DC and addition of  Propylene glycol (E1520) and Simethicone.



10 Dare of Revision of the Text:

Updated to October 2011


Updated on 05/08/2010 and displayed until 01/11/2011
Reasons for adding or updating:
  • Change to section 6.3 - Shelf life
Date of revision of text on the SPC:   29-Jul-2010
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company



Section 6.3 Shelf Life:

 

 

Current:

 

6.3 Shelf life

2 years.

 

 

Updated to:

 

6.3 Shelf life

 

Blister packs composed of PVC/PVDC foil backed with aluminium foil: 3 years

Blister packs composed of PP foil backed with aluminium foil: 4 years

Updated on 03/08/2010 and displayed until 05/08/2010
Reasons for adding or updating:
  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 6.1 - List of excipients
  • Change to section 6.3 - Shelf life
  • Change to section 6.5 - Nature and contents of container
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text
  • Change to improve clarity and readability
Date of revision of text on the SPC:   12-Jul-2010
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company



In section 1 (name of the medicinal product), the name has been changed to “Beta-Adalat 20mg/50mg Capsules”

 

In section 2 (qualitative and quantitative composition), the following changes have been made:

BEFORE:

“One capsule contains 20 mg nifedipine and 50 mg atenolol.

 

For excipients see 6.1.”

 

AFTER:

“Each hard capsule contains 20 mg nifedipine and 50 mg atenolol.

 

Excipients: Contains 10mg lactose monohydrate per capsules

 

For a full list of excipients, see Section 6.1.”

 

The following changes have been made to section 3 (Pharmaceutical form):

BEFORE:

“Capsule, hard.

 

Brown-reddish, opaque gelatin capsules overprinted with “BETA-ADALAT” and the Bayer cross.”

 

AFTER:

“Capsule, hard (capsule).

 

Brown-reddish, opaque gelatin capsules overprinted with “BETA-ADALAT” and the Bayer cross, containing white granules and a pink film-coated, round, biconvex tablet.”

 

In section 6.1 (List of excipients), the following changes have been made:

BEFORE:

“Nifedipine tablets:

 

Microcrystalline cellulose

Maize starch

Lactose

Polysorbate 80

Magnesium stearate

Hypromellose

Macrogol 4000

Titanium dioxide (E171)

Red iron oxide (E172)

 

Atenolol granules:

 

Heavy magnesium carbonate

Maize starch

Sodium laurilsulfate

Gelatin

Magnesium stearate

 

Capsule shell:

 

Red iron oxide (E172)

Titanium dioxide (E171)

Gelatin”

 

AFTER:

“Nifedipine tablets:

 

Microcrystalline cellulose (E460)

Maize starch

Lactose monohydrate

Polysorbate 80 (E433)

Magnesium stearate (E572)

Hypromellose (E464)

Macrogol 4000

Titanium dioxide (E171)

Red iron oxide (E172)

 

Atenolol granules:

 

Magnesium carbonate, heavy

Maize starch

Sodium laurilsulfate

Gelatin

Magnesium stearate (E572)

 

Capsule shell:

 

Red iron oxide (E172)

Titanium dioxide (E171)

Gelatin

 

Printing ink:

 

Shellac glaze

Titanium dioxide (E171)

Soya lecithin

Antifoam DC

 

In section 6.3 (Shelf life);

 “Blister packs composed of PVC/PVDC foil backed with aluminium foil: 3 years.

Blister packs composed of PP foil backed with aluminium foil: 2 years.”

has been changed to: “2 years.”

 

In section 6.5 (Nature and contents of container), the following changes have been made:

BEFORE:

“Blister packs composed of PVC/PVDC foil, backed with aluminium foil, each containing 28 capsules.

Blister packs composed of PP foil, backed with aluminium foil, each containing 28 capsules.”

 

AFTER:

“Blister packs composed of PP foil, backed with aluminium foil, each containing 28 capsules.”

 

In section 9 (Date of first authorisation/renewal of the authorisation), the date of last renewal has been changed to “3rd October 2008”

 

The date of revision of the text (Section 10) has been changed to “July 2010”

 

The SPC has also been updated to improve readability.

 

 

 

Updated on 03/06/2008 and displayed until 03/08/2010
Reasons for adding or updating:
  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - MA number
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   01/2008
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

Section 7, Section 8, Section 9 and Section 10 were changed to:
7. Marketing Authorisation Holder
Bayer Limited
The Atrium
Blackthorn Road
Dublin 18

8. Marketing Authorisation Number
PA 1410/026/001

9. Date of First Authorisation / Renewal of the Authorisation
Date of first authorisation:  03 October 1988
Date of last renewal:   03 October 2003

10. Date of Revision of the Text
January 2008

Updated on 01/03/2007 and displayed until 03/06/2008
Reasons for adding or updating:
  • Change to section 4.3 - Contraindications
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   04/2005
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

The changes that have been made are purely administrative and include an update of the headings for section 4.3 ('contra-indications' to 'contraindications'), section 6.6 ('instructions for use and handling' to 'special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product'), section 9 ('Date of first authorisation/renewal of authorisation' to 'Date of first authorisation/renewal of the authorisation') and section 10 ('Date of (partial) revision of the text' to 'Date of revision of the text').

Updated on 18/05/2005 and displayed until 01/03/2007
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text
Updated on 15/03/2005 and displayed until 18/05/2005
Reasons for adding or updating:
  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 6.1 - List of excipients
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 7 - Marketing authorisation holder
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text
Updated on 15/04/2004 and displayed until 15/03/2005
Reasons for adding or updating:
  • Change to section 6.3 - Shelf life
  • Change to section 6.5 - Nature and contents of container
Updated on 29/05/2003 and displayed until 15/04/2004
Reasons for adding or updating:
  • New SPC for new product

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Nifedipine
   Atenolol

Versions

 
01/11/2011 to Current
05/08/2010 to 01/11/2011
03/08/2010 to 05/08/2010
03/06/2008 to 03/08/2010
01/03/2007 to 03/06/2008
18/05/2005 to 01/03/2007
15/03/2005 to 18/05/2005
15/04/2004 to 15/03/2005
29/05/2003 to 15/04/2004
  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo